Richard has been with the New York Post since 2022. A Long Island native, prior to joining The Post, he spent four years in the US Marine Corps as a rifleman and graduated from Pace University with a ...
Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback